Irina Staatz
Chairman
Molecular Biology
Blink Biomedical
France
Biography
more than 20 years of experience in the pharmaceutical and biotechnology industry. Since 2006 she has specialized in advising and supporting leading VC firms as well as international biotech and pharmaceutical companies in the strategy and the operations of their project / product licensing, collaborations and divestment/acquisitions including M&A. Irina has successfully negotiated a broad variety of agreements. Prior to her own business she held various senior management positions in product development, international marketing and business development at Hermal (Merck KGaA), Boots Healthcare International and Knoll (later Abbott) and served as CEO of the biotechnology companies Scil Technology as well as U3 Pharma which she sold to Daiichi Sankyo. Irina serves as Vice Chairman of the Board of the public French biotech company Innate Pharma and Chairman of BliNK Therapeutics, UK.
Research Interest
Molecular Biology,Biotechnology
